Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Parkinson disease Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Primary severe restless legs syndrome Clinical criteria: Patient must manifest all 4 diagnostic criteria for Restless Legs Syndrome, AND Patient must have a baseline International Restless Legs Syndrome Rating Scale (IRLSRS) score greater than or equal to 21 points prior to initiation of pramipexole. The date and IRLSRS score must be documented in the patient's medical records at the time pramipexole treatment is initiated. The diagnostic criteria for Restless Legs Syndrome are: (a) An urge to move the legs usually accompanied or caused by unpleasant sensations in the legs; and (b) The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting; and (c) The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues; and (d) The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur during the evening or night.
“Pramipexole is a dopamine agonist that binds with high selectivity and specificity to the dopamine D2 subfamily receptors and has a preferential affinity to D3 receptors.”
“The terminal elimination half-life is about 8 hours in young healthy volunteers and about 12 hours in elderly volunteers (see section 5.2 Pharmacokinetic properties; Special populations).”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.